UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 12, 2022

MIRATI THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware	001-35921	46-2693615
(State of incorporation)	(Commission File No.)	(IRS Employer Identification No.)

3545 Cray Court, San Diego, California 92121

(Address of principal executive offices and zip code)

Registrant’s telephone number, including area code: (858) 332-3410

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class	Trading Symbol	Name of Each Exchange on Which Registered
Common Stock	MRTX	The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On May 12, 2022, our 2022 Equity Incentive Plan (the “2022 Plan”) was approved, among other things, as the successor to the 2013 Equity Incentive Plan.

The foregoing description of the 2022 Plan does not purport to be complete and is qualified in its entirety by reference to the 2022 Plan, attached to this Current Report on Form 8-K as Exhibit 99.1.

Item 5.07 Submission of Matters to a Vote of Security Holders.

Our 2022 Annual Meeting of Shareholders (the "Annual Meeting") was held on May 12, 2022. We had 55,507,835 shares of common stock outstanding and entitled to vote as of March 15, 2022, the record date for the Annual Meeting. At the Annual Meeting, 49,643,694 shares of common stock were present or represented by proxy.

At the Annual Meeting, shareholders:

(1) elected David Meek; Faheem Hasnain; Charles M. Baum, M.D., Ph.D.; Bruce L.A. Carter, Ph.D.; Julie M. Cherrington, Ph.D.; Aaron I. Davis; Henry J. Fuchs, M.D.; Craig Johnson; Maya Martinez-Davis; and Shalini Sharp as directors to hold office until the 2023 Annual Meeting of Shareholders;

(2) approved, on an advisory basis, the compensation paid to our named executive officers as disclosed in the proxy statement;

(3) ratified the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2022; and

(4) approved the 2022 Plan.

The following sets forth detailed information regarding the final results of the voting for the Annual Meeting:

Proposal 1. Election of Directors

Name	Votes For	Votes Withheld	Broker Non-Votes
David Meek	46,556,293	775,299	2,312,102
Faheem Hasnain	32,136,313	15,195,279	2,312,102
Charles M. Baum, M.D., Ph.D.	47,093,389	238,203	2,312,102
Bruce L.A. Carter, Ph.D.	41,808,580	5,523,012	2,312,102
Julie M. Cherrington, Ph.D.	47,042,222	289,370	2,312,102
Aaron I. Davis	37,992,711	9,338,881	2,312,102
Henry J. Fuchs, M.D.	46,525,651	805,941	2,312,102
Craig Johnson	41,529,372	5,802,220	2,312,102
Maya Martinez-Davis	47,034,918	296,674	2,312,102
Shalini Sharp	46,982,938	348,654	2,312,102

Proposal 2. Advisory Vote on Executive Compensation    

Votes For	Votes Against	Abstentions	Broker Non-Votes
40,105,611	7,224,198	1,783	2,312,102

Proposal 3. Ratification of the Selection of Independent Registered Public Accounting Firm

Votes For	Votes Against	Abstentions	Broker Non-Votes
45,981,353	3,662,327	14	—

Proposal 4. Approval of 2022 Equity Incentive Plan

Votes For	Votes Against	Abstentions	Broker Non-Votes
33,996,913	13,333,422	1,257	2,312,102

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	Description
99.1	2022 Equity Incentive Plan, Form of Stock Option Grant Notice and Stock Option Agreement, Form of RSU Grant Notice with Sell to Cover Election and Award Agreement, and Form of RSU Grant Notice and Award Agreement, thereunder.
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: May 12, 2022	Mirati Therapeutics, Inc.
	By:	/s/ Reena R. Desai
		Reena R. Desai
		Chief Legal Officer and Corporate Secretary